Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
4,121
3,979
3,674
3,589
3,376
3,118
Croissance des revenus (H/H)
8%
8%
2%
6%
8%
17%
Coût des ventes
1,802
1,764
1,617
1,580
1,375
1,364
Bénéfice brut
2,319
2,215
2,057
2,008
2,000
1,753
Vente, Général et Administration
1,129
1,097
1,020
954
815
789
Recherche et développement
500
491
460
446
385
398
Frais d'exploitation
1,809
1,603
1,496
1,421
1,216
1,200
Autres revenus (charges) non opérationnels
11
10
0
-2
1
1
Bénéfice avant impôts
509
579
437
580
774
524
Charge d'impôt sur le revenu
138
154
114
140
175
121
Bénéfice net
378
432
357
452
601
404
Croissance du bénéfice net
-8%
21%
-21%
-25%
49%
49%
Actions en circulation (diluées)
118.9
118.76
118.8
118.44
118.89
118.59
Variation des actions (H-H)
0%
0%
0%
0%
0%
0%
EPS (dilué)
3.17
3.63
3.01
3.82
5.06
3.41
Croissance du EPS
-8%
21%
-21%
-25%
48%
48%
Flux de trésorerie libre
438
321
107
188
534
305
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
56.27%
55.66%
55.98%
55.94%
59.24%
56.22%
Marge opérationnelle
12.37%
15.35%
15.26%
16.35%
23.22%
17.7%
Marge bénéficiaire
9.17%
10.85%
9.71%
12.59%
17.8%
12.95%
Marge du flux de trésorerie libre
10.62%
8.06%
2.91%
5.23%
15.81%
9.78%
EBITDA
984
936
731
654
842
762
Marge EBITDA
23.87%
23.52%
19.89%
18.22%
24.94%
24.43%
D&A pour le résultat opérationnel
474
325
170
67
58
210
EBIT
510
611
561
587
784
552
Marge EBIT
12.37%
15.35%
15.26%
16.35%
23.22%
17.7%
Taux d'imposition effectif
27.11%
26.59%
26.08%
24.13%
22.6%
23.09%
Statistiques clés
Clôture préc.
$112.57
Prix d'ouverture
$112.57
Plage de la journée
$112.57 - $112.57
Plage de 52 semaines
$111.1 - $152
Volume
3
Volume moyen
40
BPA (TTM)
3.69
Rendement en dividend
--
Capitalisation boursière
$13.3B
Qu’est-ce que Biomerieux 69 Marcy L'Etoile ?
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.